Results 231 to 240 of about 8,660,824 (403)

04. Development Of A Bone Marrow-resident Cell Therapy For Tissue Repair During Genetic Heterotopic Ossification

Pratik Koirala, Ziyu Chen, Mengfan Wu, Samerender Nagam Hunamantharao, Ashley E. Siegel, David E. Maridas, Vicki Rosen, Shailesh Agarwal   +7 more
openalex   +1 more source

Genetic screening for single-cell variability modulators driving therapy resistance [PDF]

, 2019
Eduardo A. Torre, Eri Arai, Sareh Bayatpour, Lauren E. Beck, Benjamin Emert, Sydney M. Shaffer, Ian A. Mellis, Mitchell E. Fane, Gretchen M. Alicea, Krista A. Budinich, Ashani T. Weeraratna, Junwei Shi, Arjun Raj   +12 more
openalex   +1 more source

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases

Clinical Cancer Research, 2017
C. Ng, F. Bidard, S. Piscuoglio, F. Geyer, R. Lim, Ino de Bruijn, R. Shen, F. Pareja, Samuel H. Berman, Lu Wang, J. Pierga, A. Vincent‐Salomon, A. Viale, L. Norton, B. Sigal, B. Weigelt, P. Cottu, J. Reis-Filho   +17 more
semanticscholar   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

DIHYDROPTERIDINE REDUCTASE DEFICIENCY: CLONING OF THE DIHYDROPTERIDINE REDUCTASE GENE, ANALYSIS OF MUTANT CELLS, AND PROSPECTS FOR GENETIC THERAPY [PDF]

, 1987
Fred D. Ledley, Jean L. Lockyer, Seymour Kaufman, Sheldon Milstein, Savio L.C. Woo   +4 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

‘Genetic profiling’ and ovarian cancer therapy (Review)

, 2011
Massimo Libra
openalex   +2 more sources

Concurrent oral 3 - Environmental and genetic factors: OP16. In Patients with Early Inflammatory Polyarthritis, Younger Age, Acpa Positivity, Shared Epitope, And Inefficacy of the First Dmard are Associated with the Need to Start a Biological Therapy: Results from the Norfolk Arthritis Register (NOAR) [PDF]

, 2011
SMM Verstappen, Mark Lunt, Diane Bunn, David G. I. Scott, Deborah Symmons, A. J. Kinloch, William Brintnell, S. Alzabin, Elizabeth Wilson, L Barran, Natalia Wegner, D. A. Bell, Ewa Cairns, P J Venables, Louise Mercer, Rebecca Davies, Mark Lunt, James Galloway, Kath Watson, William G Dixon, Alex J. MacGregor, Geoffrey R. Guile, Jane Skinner, Susan J. Fairweather‐Tait, Amy Mulick, B. Richards, Tim D. Spector, Wenxin Wang, Stephanie F Ling, Sarang Chitale, David Sharpley, Robert J. Moots, C. Estrach, Nicola Goodson, Derek L. Mattey, S. R. Dawson, Emma L. Healey, Jon Packham, S. R. Dawson, E. L. Healey, J. C. Packham   +40 more
openalex   +1 more source

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

The Lancet, 2015
J. Mega, N. Stitziel, J. G. Smith, D. Chasman, M. Caulfield, James J Devlin, F. Nordio, Craig L. Hyde, Christopher P. Cannon, F. Sacks, Neil R. Poulter, P. Sever, P. Ridker, E. Braunwald, O. Melander, S. Kathiresan, M. Sabatine   +16 more
semanticscholar   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source